Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
11/1999
11/30/1999US5993807 Truncated aspartase enzyme derivatives and uses thereof
11/30/1999US5993806 Method of stabilizing pharmaceutical preparations comprising digestive enzyme mixtures
11/30/1999US5993804 Pharmaceutically acceptable fixed-dried human blood platelets
11/30/1999US5993803 Method of reducing the severity of host vs graft reaction by down-regulating hsp60 autoimmunity
11/30/1999US5993801 Gene therapy using stromal cells
11/30/1999US5993800 Methods for prolonging the expression of a heterologous gene of interest using soluble CTLA4 molecules and an antiCD40 ligand
11/30/1999US5993798 Treatment of carcinoma and lymphoma.
11/30/1999US5993783 Aerosols
11/30/1999CA2079077C Tissue glue prepared by using cryoprecipitate
11/30/1999CA2030795C Novel physiologically active peptide and calcium metabolism-regulating agent comprising said peptide as effective ingredient
11/30/1999CA2019035C Stabilized radiopharmaceutical compositions
11/30/1999CA1340834C Derivatives of human/bovine basic fibroblast growth factor
11/30/1999CA1340831C Ribozymes
11/26/1999CA2272840A1 Association of a retinoid with a histidine derivative
11/25/1999WO1999060407A1 Assays, methods and means for modulating e2f activity
11/25/1999WO1999060405A1 Method for diagnosis and treatment of cancer
11/25/1999WO1999060171A1 Compounds, screening methods, and uses involving anti-apoptotic genes and gene products
11/25/1999WO1999060133A2 Human nucleic acid methylases
11/25/1999WO1999060132A1 Mimotopes of hypervariable region 1 of the e2 glycoprotein of hcv and uses thereof
11/25/1999WO1999060130A1 Expression of recombinant trypanosoma cruzi complement regulatory protein (crp)
11/25/1999WO1999060128A1 Il-2 selective agonists and antagonists
11/25/1999WO1999060127A2 Il-17 homologous polypeptides and therapeutic uses thereof
11/25/1999WO1999060126A2 Protein z-dependent protease inhibitor
11/25/1999WO1999060125A2 Secreted proteins
11/25/1999WO1999060124A2 Differentiation-associated sequences and methods of use therefor
11/25/1999WO1999060120A2 Soluble t cell receptor
11/25/1999WO1999060119A2 Multivalent t cell receptor complexes
11/25/1999WO1999060118A1 GABAA RECEPTOR ε2 SUBUNIT
11/25/1999WO1999060117A2 Prax-1 polypeptide
11/25/1999WO1999060116A1 Nucleic acid encoding protein, down-regulated in metastasis (drim), and its diagnostic and therapeutic use
11/25/1999WO1999060115A2 Proteins and genes useful as tumor markers
11/25/1999WO1999060105A1 Flat sheet cell encapsulation device
11/25/1999WO1999060101A1 Isolated stealth viruses and related vaccines
11/25/1999WO1999060097A1 clpX OF $i(STREPTOCOCCUS PNEUMONIAE)
11/25/1999WO1999060024A1 Methods for amyloid removal using anti-amyloid antibodies
11/25/1999WO1999060023A1 Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases
11/25/1999WO1999060021A2 Use of activated t cells, nervous system-specific antigens for treating disorders of the nevrous system
11/25/1999WO1999060020A1 Secreted proteins and polynucleotides encoding them
11/25/1999WO1999060019A1 HUMAN EDG3sb GENE
11/25/1999WO1999060017A2 Human tumour-derived polypeptide hormone phosphatonin
11/25/1999WO1999060016A2 Antimicrobial cationic peptide derivatives of bactenecin
11/25/1999WO1999060015A1 Imidazolidine derivatives, the production thereof, their use and pharmaceutical preparations containing the same
11/25/1999WO1999060013A2 Il-6 antagonist peptides
11/25/1999WO1999060012A1 Compositions and methods for non-parenteral delivery of oligonucleotides
11/25/1999WO1999060011A1 Secretion of toxins by gram-negative bacteria
11/25/1999WO1999060010A1 Compositions and methods for the pulmonary delivery of nucleic acids
11/25/1999WO1999060008A1 Cytosine deaminase gene
11/25/1999WO1999059989A1 Process for the preparation of a benzo fused heterocyclo sulfonyl halide intermediate
11/25/1999WO1999059964A1 Novel analogs of 16-hydroxyeicosatetraenoic acid
11/25/1999WO1999059633A1 Therapeutics using a bispecific anti-hla class ii invariant chain x anti-pathogen antibody
11/25/1999WO1999059632A1 Methods and use of compositions comprising tnf-rii(p75) agonists for treating asthma and other allergic conditions
11/25/1999WO1999059631A1 Prevention and treatment of hypergastrinemia
11/25/1999WO1999059629A1 Humanized antibodies that recognize verotoxin ii and cell line producing same
11/25/1999WO1999059628A2 Combination therapy for the treatment of tumors
11/25/1999WO1999059625A1 Vaccine delivery system
11/25/1999WO1999059623A1 Methods and means for preventing or treating inflammation or pruritis
11/25/1999WO1999059622A1 Treatment for hemophilia
11/25/1999WO1999059621A1 Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having g chronic hepatitis c infection
11/25/1999WO1999059620A1 Angiostatin receptor
11/25/1999WO1999059619A1 Acrp30r1: a homolog of acrp30 (30 kd adipocyte complement-related protein)
11/25/1999WO1999059618A1 Acrp30r1l, a homolog of acrp30 (30 kd adipocyte complement-related protein)
11/25/1999WO1999059617A2 Immunoregulator
11/25/1999WO1999059616A1 Enhancement of oxazolidinone antibacterial agents activity by using arginine derivatives
11/25/1999WO1999059615A1 Hybrid polypeptides with enhanced pharmacokinetic properties
11/25/1999WO1999059614A1 Modulation of angiogenesis and wound healing
11/25/1999WO1999059613A1 BINDING MOIETIES FOR UROKINASE PLASMINOGEN ACTIVATOR (uPA)
11/25/1999WO1999059612A1 Method for the treatment of gastroesophageal reflux disease
11/25/1999WO1999059611A1 Compositions and methods for prevention and treatment of uncontrolled formation of intravascular fibrin clots
11/25/1999WO1999059610A2 Use of lipopeptides or lipoproteins for wound treatment
11/25/1999WO1999059609A2 Use of hmg proteins for the preparation of medicaments having cytotoxic activity
11/25/1999WO1999059608A2 Osteoporosis treatment
11/25/1999WO1999059586A1 Thiazolidine and oxazolidine derivatives for the treatment of acute myocardial infarction and inhibition of cardiomyocyte apoptosis
11/25/1999WO1999059570A1 Protease inhibitors
11/25/1999WO1999059565A1 Novel compositions
11/25/1999WO1999059559A1 Independent regulation of basal and insulin-stimulated glucose transport
11/25/1999WO1999059549A1 Biodegradable sustained-release alginate gels
11/25/1999WO1999059548A1 Controlled drug delivery system using the conjugation of drug to biodegradable polyester
11/25/1999WO1999059545A1 Targeted liposomal drug delivery system
11/25/1999WO1999059543A1 A pharmaceutical formulation for nasal administration
11/25/1999WO1999059541A2 Cyclosporin preparations
11/25/1999WO1999059526A2 Protease inhibitors
11/25/1999WO1999059523A2 Topical pharmaceutical compositions useful for the treatment of cutaneous or circulatory pathologies on inflammatory, immune, proliferative or degenerative basis
11/25/1999WO1999051051A3 A method for controlling connections to a mobile station
11/25/1999WO1999050298A9 GFRα-X, A NOVEL GLIAL-DERIVED NEUROTROPHIC FACTOR RECEPTOR AND USES THEREFOR
11/25/1999WO1999048523A3 Antagonists of the inflammatory mediator oncostatin m (osm)
11/25/1999WO1999048515A9 Trimeric antigenic o-linked glycopeptide conjugates, methods of preparation and uses thereof
11/25/1999WO1999047925A3 Methods and compositions for diagnosis of rheumatoid arthritis
11/25/1999WO1999047545A3 Inhibitors of caspases
11/25/1999WO1999047158A3 Therapeutic chemokine receptor antagonists
11/25/1999WO1999045128A8 Chimeric proteins with cell-targeting specificity and apoptosis-dinducing activities
11/25/1999WO1999043832A3 Human proteinase molecules
11/25/1999WO1999043808A8 Human c-maf compositions and methods of use thereof
11/25/1999WO1999043344A3 Matrix protein compositions for wound healing
11/25/1999WO1999040881A3 Specific antibodies against mammary tumor-associated mucin, method for production and use
11/25/1999WO1999040199A3 A novel fungal protein critical for expression of fungal proteins
11/25/1999WO1999039740A9 Sensitizing cells to compounds using lipid-mediated gene and compound delivery
11/25/1999WO1999038976A3 Human growth factor homologs
11/25/1999WO1999037766A3 A purified polynucleotide sequence containing a region encoding a mutated zap-70 protein or a fragment thereof
11/25/1999WO1999005527A3 Methods for diagnosis and therapy of autoimmune disease, such as insulin dependent diabetes mellitus, involving retroviral superantigens
11/25/1999WO1998041226A9 Pharmaceutical combined preparations containing erythropoietin and iron preparations
1 ... 2450 2451 2452 2453 2454 2455 2456 2457 2458 2459 2460 2461 2462 2463 2464 2465 2466 2467 2468 2469 2470 ... 3163